Abstract
We expressed a recombinant peptide fragment (Ser445–Val733) of human von Wille-brand factor (vWF), containing the binding domain for the platelet receptor of GP Ib, in E. coli. This 33 kD peptide blocks binding of the intact vWF molecule to GP Ib in the presence of modulators. Thus, it offers potential as an antithrombotic agent. High level expression was achieved in a plasmid construct driven by the bacteriophage T7 promoter. The peptide was solubilized from inclusion bodies in strong chaotrope, then reduced and alkylated. Following purification, formulation at pH 3.5, and lyophilization, the reconstituted experimental product (RG 12986) exists as an equilibrium of monomer and dimer species. When formulated above pH 5.0, soluble aggregates are formed; these solutions have less bioactivity than RG 12986. Interestingly, the non-aggregated state of RG 12986 remains conserved following dilution and incubation with platelet-poor plasma. The overall purification/low pH formulation strategies may be applicable to other E. coli recombinant proteins having a tendency to aggregate following removal of chaotrope near physiologic pH when in a concentrated format.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ruggeri, Z.M. and Zimmerman, T. 1985. Platelets and von Willebrand disease. Semin. Hematol. 22: 203–218.
Bellinger, D., Nichols, T., Read, M., Reddick, R., Lamb, M., Brinkhous, K., Evatt, B. and Griggs, T. 1987. Prevention of occlusive coronary artery thrombosis by a murine monoclonal antibody to porcine von Willebrand factor. Proc. Natl. Acad. Sci. USA 84: 8100–8104.
Weiss, H.J., Tschopp, T.B., Baumgartner, H.R., Sussman, I.I., Johnson, M.M. and Egan, J.J. 1974. Decreased adhesion of giant (Bernard-Soulier) platelets to subendothelium. Further implications on the role of the von Willebrand factor in hemostasis. Am. J. Med. 57: 920–925.
Mohri, H., Fujimura, Y., Shima, M., Yashioka, A., Houghten, R., Ruggeri, Z. and Zimmerman, T. 1988. Structure of von Willebrand factor domain interacting with glycoprotein Ib. J. Biol. Chem. 263: 17901–17904.
Mohri, H., Yoshioka, A., Zimmerman, T. and Ruggeri, Z. 1989. Isolation of the von Willebrand factor domain interacting with platelet glycoprotein Ib, heparin and collagen and characterization of its three distinct functional sites. J. Biol. Chem. 264: 17361–17367.
Fujimura, Y., Titani, K., Holland, L., Roberts, J., Kastel, P., Ruggeri, Z. and Zimmerman, T. 1987. A heparin binding domain of Human von Willebrand factor. Blood 70: 985–988.
Plétu, G., Meuller, P., Cherel, G., Diaz, J., Baruch, D., Courtney, M. and Meyer, D. 1989. Production in E coli of a biologically active subfragment of von Willebrand factor corresponding to the platelet glycoprotein Ib, collagen and heparin binding domains. Biochem. Biophys. Res. Commun. 164: 1339–1347.
Sugimoto, M., Ricca, G., Hrinda, M., Schreiber, A., Searfoss, G. and Ruggeri, Z. 1990. Functional modulation of the isolated glycoprotein Ib binding domain of von Willebrand factor expressed in Escherichia coli. Biochemistry 30: 5202–5209.
Studier, F.W. and Moffett, B.A. 1986. Use of bacteriophage TV RNA polymerase to direct selective high-level expression of cloned genes. J. Mol. Biol. 189: 113–130.
Jung, G., Denefle, P., Becquart, J. and Mayaux, J.-F. 1988. High-cell density fermentation studies of recombinant E. colistrains expressing human interleukin-1B. American Institute Pasteur/Microbiology 139: 129–146.
Laemmli, U.K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680–685.
Towbin, H., Staehelin, T. and Gordon, J. 1979. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc. Natl Acad. Sci. USA 76: 4350–4354.
Marguerie, G.A., Plow, E.F. and Edgington, T.S. 1979. Human platelets possess an inducible and saturable receptor specific for Fibrinogen. J. Biol. Ghem. 254: 5357–5363.
Ruggeri, Z.M., De Mario, L., Gatti, L., Bader, R. and Montgomery, R.R. 1983. Platelets have more than one binding site for von Willebrand factor. J. Clin. Invest. 72: 1–12.
Brinkhous, K.M., Read, M.S., Fricke, W.A. and Wagner, R.H. 1983. Botrocetin (venom coagglutinin): Reaction with a broad spectrum of multimeric forms of factor VIII macromolecular complex. Proc. Natl. Acad. Sci. USA 80: 1463–1466.
Huang, T.F., Holt, J.C., Kirby, E.P. and Niewiarowski, S., 1989. Primary structure and its inhibition of von Willebrand factor binding to glycoprotein Ilb/IIa complex on human platelets. Biochemistry 28: 661–666.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Prior, C., Chu, V., Holt, J. et al. Production and Functional Characterization of a Recombinant Fragment of Von Willebrand Factor (vWF): An Antagonist to Platelet Receptor Gp Ib. Nat Biotechnol 10, 66–73 (1992). https://doi.org/10.1038/nbt0192-66
Issue Date:
DOI: https://doi.org/10.1038/nbt0192-66
